-
Capital, M&A & Industry Strategy1 week agoBiotech is booming — and startups are still dying
Despite an uptick in dealmaking and IPOs, a selective funding market and scientific setbacks are still pushing some biotechs to the brink.
-
Capital, M&A & Industry Strategy1 week agoSTAT+: Pharmalittle: We’re reading about Roche investments in Germany, a Gilead bowel disease drug, and more
Roche is reviewing all future investments in Germany over health care cost-cutting policies, with a top executive citing a loss of trust
-
Capital, M&A & Industry Strategy1 week agoRoche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study
Roche is paying Hansoh $400 million up front in a broad deal involving several ADCs. Elsewhere, another top investor formed a China-focused fund and Ultragenyx sold...
-
Capital, M&A & Industry Strategy1 week agoCancer biotech Nouscom adds €120m, and other financings
A €120m Series D for Swiss biotech Nouscom will support trials of a Lynch syndrome vaccine, with Soufflé, Estuary, and Microbiotica also raising cash.
-
Capital, M&A & Industry Strategy1 week agoInfections After Heart Surgery Drive Up Costs, and Payment Groups Show Where
A new study finds hospital-acquired infections after cardiovascular surgery raise costs unevenly across diagnosis-related groups, with non-ventilator lower respiratory infections dominating and medicine expenses climbing sharply...
-
Capital, M&A & Industry Strategy2 weeks agoAftermarket gains for City, Iambic: Public Equity Report
BIOCENTURY | FINANCEAFTERMARKET GAINS FOR CITY, IAMBIC: PUBLIC EQUITY REPORTPlus: Aspen, Bambusa enter NASDAQ queue; financings for Akeso, Verastem, First Tracks and more
-
Capital, M&A & Industry Strategy2 weeks agoRNAi biotech City hauls in $200m in upsized IPO
City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.
-
Capital, M&A & Industry Strategy2 weeks agoThis week in charts: Moderna’s massive stock run
The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.
-
Capital, M&A & Industry Strategy2 weeks agoActa Pharmaceuticals raises $24m for Alzheimer’s therapies
It is a gamma-secretase modulator being developed as a potent once-daily oral therapy for the treatment and potential prevention of AD. According to the company, existing...
-
Capital, M&A & Industry Strategy2 weeks agoRadiotherapy Leaves a Lasting Inflammatory Signature in the Saliva of Head and Neck Cancer Patients
A new study finds that radiotherapy persistently raises pro-inflammatory cytokines in the saliva of head and neck cancer patients, mirroring inflammatory changes in mouse salivary glands...
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
